The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

After a Type C discussion, Blue Lake got the FDA nod to enrol both RSV-positive and negative children above the age of 18 months in the study. This leaves the US-based biotech open to potentially ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Moderna, Inc. is placed among them. Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, ...

You are correct that there is underreporting of adverse effects from vaccines; however, in the vast majority of cases, the ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...

It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.